866-997-4948(US-Canada Toll Free)

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 83 Pages

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H2 2017

Summary

According to the recently published report 'T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2017'; T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production is induced by the binding of CD28.

The report 'T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2017' outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Autoimmune Disorders, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Breast Cancer, Dermatomyositis, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener Polyangiitis), Hepatocellular Carcinoma, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Juvenile Rheumatoid Arthritis, Lupus Nephritis, Myasthenia Gravis, Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polymyositis/Idiopathic Inflammatory Myopathy, Renal Cell Carcinoma, Sarcoidosis, Sicca Syndrome (Sjogren), Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes), Uveitis and Vitiligo.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)
- The report reviews T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Overview 7
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Therapeutics Assessment 18
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Companies Involved in Therapeutics Development 23
3SBio Inc 23
BioAtla LLC 23
Bristol-Myers Squibb Co 23
KAHR medical Ltd 24
MedImmune LLC 25
Mologen AG 25
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Drug Profiles 26
abatacept - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
abatacept biosimilar - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
abatacept biosimilar - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
abatacept biosimilar - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
CUE-201 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
KAHR-102 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
KN-019 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
MEDI-5265 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
MGN-1601 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Monoclonal Antibody to Inhibit CTLA-4 for Oncology - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Vaccine to Target CD80 and IL-2 for Acute Myeloblastic Leukemia - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Dormant Products 50
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Discontinued Products 52
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Product Development Milestones 53
Featured News & Press Releases 53
Nov 13, 2017: Bristol-Myers Squibbs Orencia Rejects For Use Within NHS Scotland 53
Nov 02, 2017: Bristol-Myers Squibb to Showcase Company's Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting 53
Jul 26, 2017: Bristol-Myers Squibbs ORENCIA (abatacept) Receives Second European Commission Approval in Less than a Year - New Approval for Treatment of Active Psoriatic Arthritis 59
Jul 06, 2017: Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults 59
Jun 14, 2017: Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017) 61
Jun 08, 2017: Bristol-Myers Squibb Announces Availability of New ORENCIA (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis 65
Mar 13, 2017: Bristol-Myers Squibb's Orencia Rejects For Use Within NHS Scotland 67
Nov 14, 2016: Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting 67
Nov 10, 2016: Bristol-Myers Squibb to Showcase New Data Spanning Rheumatoid Arthritis and Other Autoimmune Diseases at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting 68
Sep 06, 2016: European Commission Approves Bristol-Myers Squibbs ORENCIA (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate 72
Jul 25, 2016: CHMP Issues Positive Opinion for ORENCIA (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in the EU 73
Jul 21, 2016: CHMP adopts extension to existing therapeutic indication for Orencia 74
Jul 20, 2016: Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA (abatacept) ClickJect, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis 75
Jun 08, 2016: Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016) 76
May 25, 2016: Launch of Orencia SC 125 mg Auto-injector 1 mL for Treatment of Rheumatoid Arthritis 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indications, H2 2017 10
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
Number of Products under Investigation by Universities/Institutes, H2 2017 16
Products under Investigation by Universities/Institutes, H2 2017 17
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Stage and Route of Administration, H2 2017 20
Number of Products by Stage and Molecule Type, H2 2017 22
Pipeline by 3SBio Inc, H2 2017 23
Pipeline by BioAtla LLC, H2 2017 23
Pipeline by Bristol-Myers Squibb Co, H2 2017 24
Pipeline by KAHR medical Ltd, H2 2017 25
Pipeline by MedImmune LLC, H2 2017 25
Pipeline by Mologen AG, H2 2017 25
Dormant Products, H2 2017 50
Dormant Products, H2 2017 (Contd..1), H2 2017 51
Discontinued Products, H2 2017 52

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Routes of Administration, H2 2017 19
Number of Products by Stage and Routes of Administration, H2 2017 19
Number of Products by Molecule Types, H2 2017 21
Number of Products by Stage and Molecule Types, H2 2017 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *